Quantum Biopharma Ltd. | WebDisclosure

Basculer en Français

10855	Companies
235900	Keywords
164845	Articles
126462	Press releases

Headlines Articles Press releases Quantum Biopharma Ltd.

Home
Companies
Quantum Biopharma Ltd.

PRESS RELEASE

published on 12/20/2024 at 15:15, 1 year 7 months ago

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
Quantum BioPharma Ltd. purchases $1,000,000 Bitcoin and other cryptocurrencies, allows cryptocurrency transactions, emphasizing compliance and potential returns for shareholders

Bitcoin Compliance Investment Cryptocurrency Quantum BioPharma
BRIEF

published on 12/14/2024 at 01:05, 1 year 8 months ago

Quantum BioPharma conclut la première tranche de son offre

Première Tranche Biopharmacie Quantique Unités D'obligations Développement Du Capital Dollars Canadiens
BRIEF

published on 12/14/2024 at 01:05, 1 year 8 months ago

Quantum BioPharma Concludes Initial Tranche of Offering

First Tranche Capital Development Quantum BioPharma Canadian Dollars Debenture Units
PRESS RELEASE

published on 12/14/2024 at 01:00, 1 year 8 months ago

Quantum Biopharma Announces Closing of First Tranche
Quantum BioPharma closes initial tranche of offering, issuing 500 Debenture Units for $500,000. Proceeds for business development and working capital. Securities subject to statutory hold period

Working Capital Statutory Hold Period Quantum BioPharma Debenture Units Tranche Offering
BRIEF

published on 12/10/2024 at 13:35, 1 year 8 months ago

Quantum Biopharma avance dans l'essai clinique Lucid-MS

Recherche Biopharmaceutique Biopharmacie Quantique Examen De Sécurité Essai Lucid-MS Progrès Clinique
BRIEF

published on 12/10/2024 at 13:35, 1 year 8 months ago

Quantum Biopharma Moves Forward in Lucid-MS Clinical Trial

Biopharmaceutical Research Quantum BioPharma Lucid-MS Trial Clinical Advancement Safety Review
PRESS RELEASE

published on 12/10/2024 at 13:30, 1 year 8 months ago

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
Quantum BioPharma announces approval to proceed with dosing of second cohort in Lucid-21-302 trial. Company focused on innovative treatments for neurodegenerative disorders

Drug Development Neurodegenerative Disorders Quantum BioPharma Lucid-21-302 Trial Safety Review Committee
BRIEF

published on 12/05/2024 at 13:35, 1 year 8 months ago

Quantum BioPharma Launches Private Placement for $5 Million

Private Placement Convertible Debenture Canadian Market Investment Offering Quantum BioPharma
BRIEF

published on 12/05/2024 at 13:35, 1 year 8 months ago

Quantum BioPharma lance un placement privé de 5 millions de dollars

Placement Privé Marché Canadien Obligation Convertible Biopharmacie Quantique Offre D'investissement
PRESS RELEASE

published on 12/05/2024 at 13:30, 1 year 8 months ago

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
Quantum BioPharma announces a non-brokered private placement offering of convertible debenture units. Proceeds for business development and working capital

Private Placement Working Capital Business Development Quantum BioPharma Debenture Units

Accesswire

Published on 08/20/2026 at 02:22, 5 hours 16 minutes ago

Infrastructure Sterilisation Drilling Begins at Tunkillia
Published on 08/20/2026 at 01:00, 6 hours 38 minutes ago

Irving Resources Announces Results of AGM
Published on 08/20/2026 at 00:40, 6 hours 58 minutes ago

Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
Published on 08/19/2026 at 22:00, 9 hours 38 minutes ago

Jaguar Health Reports Second Quarter 2026 Financials
Published on 08/19/2026 at 20:35, 11 hours 3 minutes ago

Revive Therapeutics Announces Proposed Shares for Debt Settlement

View all ACCESSWIRE

EQS Group

Published on 08/20/2026 at 07:00, 37 minutes ago

1H26: Swiss Prime Site delivers a strong operating result and sustained growth; FFO I of CHF 2.15 per share (+2.4%)
Published on 08/20/2026 at 07:00, 37 minutes ago

Centiel reports strong 2026 Half-Year results and invests into future growth
Published on 08/20/2026 at 07:00, 37 minutes ago

New upcycle: SBO bookings increase in H1 despite Middle East conflict
Published on 08/20/2026 at 07:00, 37 minutes ago

NFON advances its strategic transformation in a challenging environment
Published on 08/20/2026 at 06:30, 1 hour 7 minutes ago

Pleasing operating result in first half of 2026

Les Echos

Published on 08/18/2026 at 18:00, 1 day 13 hours ago

KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 1 day 13 hours ago

Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 1 day 20 hours ago

GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Published on 08/18/2026 at 11:15, 1 day 20 hours ago

GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 2 days 11 hours ago

Aéroports de Paris S.A - July 2026 traffic figures

View all LES ECHOS COMFI WIRE